FOLH1 and prostate cancer: Besides, Kloss and colleagues generated dominant-negative TGF-βRII-modified CAR-T cells specific for prostate-specific membrane antigen (PSMA), that exhibited superior level of proliferation, cytokine secretion, resistance to dysfunctionality related to chronic inflammation, long-term in vivo persistence, and the induction of tumor eradication in aggressive human prostate cancer mouse models (25).